The Oncidium Foundation

Help us achieve our OBJECTIVE 365 LIVES by supporting 365 cancer patients over the next 5 years, representing a total of 10 million euros! Through collaborative efforts, we can achieve this mission. The RLT*-Connect Platform is an online tool that enables global donations of radiopharmaceutical-based cancer treatments, and thus, broaden the access to essential therapy for patients facing financial barriers. Radioisotope suppliers, local radiopharmacies and nuclear medicine services are already on board. Are you? **Radioligand therapy (RLT) is a targeted medical treatment that uses radioactive molecules to selectively deliver radiation directly to cancer cells. More and more RLTs are under development, and their adoption is steadily increasing as ongoing research continues to demonstrate their potential benefits in improving patient outcomes.* This Fund allows U.S. donors an income tax deduction (501(c)(3)) for their contributions, to the extent permitted by U.S. tax law. Any questions related to tax deduction please contact us: contact@oncidium-life.org THE ONCIDIUM FOUNDATION The Oncidium foundation is a non-profit, public benefit organization that aims to support and accelerate the development of radiotheranostics for cancer care, worldwide. For more information, visit the Oncidium foundation website: OncidiumFoundation.org

Enhancing access to radiotheranostics for U.S. cancer patients in supporting them and their families throughout their treatment journey, including logistics and accommodation. This Fund allows U.S. donors an income tax deduction (501(c)(3))  for their contributions, to the extent permitted by U.S. tax law. Any questions related to tax deduction please contact us: contact@oncidium-life.org Recent research and developments have shown the promising outcomes regarding the use of radiotheranostics in the cancer care landscape, with some approved products already on the market and others in early-stage development or clinical trials. However, * availability of these treatments, education and awareness of the potential use of such therapies is still very limited.* ( In the US, 177-Lutetium vipivotide tetraxetan was approved on March 2022, by the Food and Drug Administration for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)). Considering these opportunities and challenges, it is in this context that the Oncidium foundation, together with Cary's wife and daughters, have decided to open the "Cary M. Adams Fund", in honor of their late husband and father, Mr. Cary M. Adams, a firm believer in the potential of radiotheranostics-based treatments for cancer care, to support cancer patients access to radiotheranostics in the US. CARY M. ADAMS September 5, 1948 - September 9, 2022 Cary was an attorney & investor with an entrepreneurial spirit, a passion for innovation, and an unquenchable thirst for knowledge. Despite his many professional pursuits, Cary's family and community always came first. In Cary's final years, he became both an advocate for & participant in research of radiotheranostic cancer treatments. THE ONCIDIUM FOUNDATION The Oncidium foundation is a non-profit, public benefit organization that aims to support and accelerate the development of radiotheranostics for cancer care, worldwide. For more information, visit the Oncidium foundation website: OncidiumFoundation.org